A Study of MabThera (Rituximab) in Participants With Rheumatoid Arthritis Who Have Had an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARD) and/or Anti-Tumor Necrosis Factor (Anti-TNF) Therapy.

EMMS Nazareth; Internal Department A, Nazareth

Nahariya Hospital; Rheumatology Dept, Nahariya

Shaare Zedek Medical Center; Rheumatology Dept, Nahariya

Carmel Hospital; Rheumatology Dept, Haifa

Hillel Yaffe MC; Internal C - Rheumatology, Hadera

Meir Medical Center; Internal Dept A, Kfar Saba

Wolfson Hospital; Rheumatology, Holon

Kaplan Medical Center; Reumatology, Rehovot

Barzilai; Rheumatology, Ashkelon

Hadassah Mount Scopus Hospital; Rheumatology, Jerusalem

Rambam Medical Center; Rheumatology, Haifa

Bnei Zion Medical Center; Rheumatology, Haifa

Beilinson Medical Center; Rheumatology, Petah Tikva

Assaf Harofe; Dept of Medicine B, Beer Yaakov

Sourasky / Ichilov Hospital; Rheumatology, Tel Aviv

Soroka Medical Center; Reumatology, Beersheba